In a speech at the 5th Regulatory Society Meeting in Tokyo on Sept. 8, an officer of MHLW reported that 2076 facilities operated by medical corporations and individual clinics had registered for certification of cell-therapy based medical treatment. The majority were producers of platelet-rich plasma (PRP) therapy and dental clinics, but applications of regenerative medicine facilities was increasing, for clinical studies as well as for therapy such as cancer immunotherapy. MHLW will install a study group to develop a support system of clinical research.

Nikkei Biotech news release, September 8, 2015